Business Context and Reporting Period
This Form 8-K is a current report filed by Millendo Therapeutics, Inc. (noted as Tempest Therapeutics in metadata) on January 22, 2019, covering events occurring on January 15, 2019. The filing details the approval of executive compensation packages and new employment agreements by the Compensation Committee of the Board of Directors.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation data:
- 2019 Base Salaries: CEO Julia C. Owens ($478,900), CMO Pharis Mohideen ($388,800), CAO/General Counsel Jeffery M. Brinza ($346,300), and CFO Louis Arcudi III ($350,000).
- 2019 Target Non-Equity Incentive Compensation: CEO ($239,450), CMO ($155,520), CAO ($138,520), and CFO ($140,000).
- 2018 Non-Equity Incentive Compensation: CEO ($179,529), CMO ($106,788), CAO ($89,508), and CFO ($18,486, pro-rated).
- Stock Options Granted (Jan 15, 2019): CEO (173,993), CMO (64,000), CAO (56,000), and CFO (50,000).
Material Changes
The primary material change is the formalization of executive compensation effective January 1, 2019, and the execution of new employment agreements on January 15, 2019. These agreements introduce specific severance protections tied to a "change in control" or termination without cause, including salary continuation and accelerated vesting of stock options.
Guidance, Outlook, and Risks
Management Commentary and Targets: The 2019 performance targets are set as a percentage of base salary (50% for the CEO, 40% for other executives). Achievement depends on clinical development objectives and corporate goals. The 2018 bonus plan goals were achieved at an 83% level.
Employment Agreement Terms:
- Change in Control: CEO receives 18 months of salary and COBRA; other executives receive 12 months. All stock options fully vest.
- Termination Without Cause (No Change in Control): All executives receive 12 months of salary and COBRA. Note: CEO stock options granted on or after Jan 15, 2019, do not accelerate in this scenario.
Other Events: On January 17, 2019, the company issued a press release regarding inducement grants to employees.
Investor Verification Checklist
- Verify the total dilution impact of the 343,993 stock options granted to executives on January 15, 2019.
- Confirm the specific clinical development milestones required to achieve the 2019 non-equity incentive targets.
- Review the full text of the employment agreements (to be filed as exhibits to the Q1 2019 Form 10-Q) for detailed definitions of "good reason" and "change in control."
- Assess the financial impact of the 2018 bonus payout (83% achievement) on the company's cash position.